ZA200303284B - Method for producing purified hematinic iron-saccharidic complex and product produced. - Google Patents

Method for producing purified hematinic iron-saccharidic complex and product produced. Download PDF

Info

Publication number: ZA200303284B
Authority: ZA; South Africa
Prior art keywords: iron; complex; ahs; saccharidic; excipients
Prior art date: 2000-11-02

Application number

ZA200303284A

Other languages

English (en)

Inventor

Robert A Beck

Robert A Mateer

Original Assignee

Chromaceutical Advanced Tech

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-11-02

Filing date

2003-04-29

Publication date

2003-11-04

2003-04-29 Application filed by Chromaceutical Advanced Tech filed Critical Chromaceutical Advanced Tech

2003-11-04 Publication of ZA200303284B publication Critical patent/ZA200303284B/en

Links

238000004519 manufacturing process Methods 0.000 title claims description 64
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 149
239000000546 pharmaceutical excipient Substances 0.000 claims description 143
238000000034 method Methods 0.000 claims description 139
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 115
239000000203 mixture Substances 0.000 claims description 82
239000000047 product Substances 0.000 claims description 81
229910052742 iron Inorganic materials 0.000 claims description 75
238000004128 high performance liquid chromatography Methods 0.000 claims description 74
238000002356 laser light scattering Methods 0.000 claims description 74
239000000126 substance Substances 0.000 claims description 44
238000004108 freeze drying Methods 0.000 claims description 43
238000004458 analytical method Methods 0.000 claims description 34
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 33
239000005720 sucrose Substances 0.000 claims description 30
238000010828 elution Methods 0.000 claims description 29
229930006000 Sucrose Natural products 0.000 claims description 27
238000012544 monitoring process Methods 0.000 claims description 25
238000003860 storage Methods 0.000 claims description 25
229920002307 Dextran Polymers 0.000 claims description 21
238000003786 synthesis reaction Methods 0.000 claims description 21
238000000149 argon plasma sintering Methods 0.000 claims description 19
238000001514 detection method Methods 0.000 claims description 19
230000015572 biosynthetic process Effects 0.000 claims description 18
239000006227 byproduct Substances 0.000 claims description 17
239000012528 membrane Substances 0.000 claims description 15
239000002904 solvent Substances 0.000 claims description 15
230000015556 catabolic process Effects 0.000 claims description 14
238000006731 degradation reaction Methods 0.000 claims description 14
239000003085 diluting agent Substances 0.000 claims description 14
239000007788 liquid Substances 0.000 claims description 13
230000005526 G1 to G0 transition Effects 0.000 claims description 11
229940062350 sodium ferric gluconate complex Drugs 0.000 claims description 10
239000007787 solid Substances 0.000 claims description 10
238000004949 mass spectrometry Methods 0.000 claims description 8
229960004887 ferric hydroxide Drugs 0.000 claims description 7
IEECXTSVVFWGSE-UHFFFAOYSA-M iron(3+);oxygen(2-);hydroxide Chemical compound [OH-].[O-2].[Fe+3] IEECXTSVVFWGSE-UHFFFAOYSA-M 0.000 claims description 7
238000004811 liquid chromatography Methods 0.000 claims description 7
238000001914 filtration Methods 0.000 claims description 6
230000004044 response Effects 0.000 claims description 6
238000004611 spectroscopical analysis Methods 0.000 claims description 6
238000010521 absorption reaction Methods 0.000 claims description 5
239000011159 matrix material Substances 0.000 claims description 5
238000001542 size-exclusion chromatography Methods 0.000 claims description 5
238000005251 capillar electrophoresis Methods 0.000 claims description 4
230000005496 eutectics Effects 0.000 claims description 4
235000008824 ferric saccharate Nutrition 0.000 claims description 4
239000011788 ferric saccharate Substances 0.000 claims description 4
XRDYWGSODBNAIE-BQGRAUOOSA-K iron(3+);(2r,3s,4s,5s)-2,3,4,5,6-pentahydroxy-6-oxohexanoate Chemical compound [Fe+3].OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O XRDYWGSODBNAIE-BQGRAUOOSA-K 0.000 claims description 4
230000002285 radioactive effect Effects 0.000 claims description 4
239000007858 starting material Substances 0.000 claims description 4
238000000870 ultraviolet spectroscopy Methods 0.000 claims description 4
238000004435 EPR spectroscopy Methods 0.000 claims description 3
238000004566 IR spectroscopy Methods 0.000 claims description 3
238000005481 NMR spectroscopy Methods 0.000 claims description 3
230000005540 biological transmission Effects 0.000 claims description 3
238000002983 circular dichroism Methods 0.000 claims description 3
238000000840 electrochemical analysis Methods 0.000 claims description 3
238000002149 energy-dispersive X-ray emission spectroscopy Methods 0.000 claims description 3
238000000853 optical rotatory dispersion Methods 0.000 claims description 3
230000000717 retained effect Effects 0.000 claims description 3
229920001503 Glucan Polymers 0.000 claims description 2
238000003795 desorption Methods 0.000 claims description 2
238000000113 differential scanning calorimetry Methods 0.000 claims description 2
230000009477 glass transition Effects 0.000 claims description 2
238000009616 inductively coupled plasma Methods 0.000 claims description 2
150000002596 lactones Chemical class 0.000 claims description 2
238000000711 polarimetry Methods 0.000 claims description 2
238000003969 polarography Methods 0.000 claims description 2
238000005199 ultracentrifugation Methods 0.000 claims description 2
239000002699 waste material Substances 0.000 claims description 2
238000002441 X-ray diffraction Methods 0.000 claims 1
238000003491 array Methods 0.000 claims 1
238000000009 pyrolysis mass spectrometry Methods 0.000 claims 1
241000894007 species Species 0.000 description 64
239000000523 sample Substances 0.000 description 41
238000000926 separation method Methods 0.000 description 30
239000000463 material Substances 0.000 description 28
229960004793 sucrose Drugs 0.000 description 24
239000003173 antianemic agent Substances 0.000 description 23
230000008569 process Effects 0.000 description 23
230000000694 effects Effects 0.000 description 21
238000005227 gel permeation chromatography Methods 0.000 description 21
VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical class [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 20
238000012512 characterization method Methods 0.000 description 18
238000005259 measurement Methods 0.000 description 18
150000001720 carbohydrates Chemical class 0.000 description 17
239000011521 glass Substances 0.000 description 17
239000003814 drug Substances 0.000 description 15
235000013305 food Nutrition 0.000 description 14
RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 13
238000001035 drying Methods 0.000 description 13
230000003993 interaction Effects 0.000 description 13
239000012071 phase Substances 0.000 description 13
235000014633 carbohydrates Nutrition 0.000 description 12
238000002360 preparation method Methods 0.000 description 12
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 11
229920002521 macromolecule Polymers 0.000 description 11
239000000243 solution Substances 0.000 description 11
238000004587 chromatography analysis Methods 0.000 description 10
150000001875 compounds Chemical class 0.000 description 10
-1 iron ions Chemical class 0.000 description 10
239000002245 particle Substances 0.000 description 10
238000002835 absorbance Methods 0.000 description 9
239000012491 analyte Substances 0.000 description 8
238000005516 engineering process Methods 0.000 description 8
150000002772 monosaccharides Chemical class 0.000 description 8
239000008293 association colloid Substances 0.000 description 7
239000000084 colloidal system Substances 0.000 description 7
238000007710 freezing Methods 0.000 description 7
239000011148 porous material Substances 0.000 description 7
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 6
239000002253 acid Substances 0.000 description 6
230000032683 aging Effects 0.000 description 6
239000003708 ampul Substances 0.000 description 6
238000013459 approach Methods 0.000 description 6
238000006243 chemical reaction Methods 0.000 description 6
238000009826 distribution Methods 0.000 description 6
239000000174 gluconic acid Substances 0.000 description 6
235000012208 gluconic acid Nutrition 0.000 description 6
239000001257 hydrogen Substances 0.000 description 6
229910052739 hydrogen Inorganic materials 0.000 description 6
JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 6
230000005012 migration Effects 0.000 description 6
238000013508 migration Methods 0.000 description 6
230000003647 oxidation Effects 0.000 description 6
238000007254 oxidation reaction Methods 0.000 description 6
238000012545 processing Methods 0.000 description 6
238000003908 quality control method Methods 0.000 description 6
238000012360 testing method Methods 0.000 description 6
CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 5
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
230000008859 change Effects 0.000 description 5
230000007423 decrease Effects 0.000 description 5
230000001687 destabilization Effects 0.000 description 5
238000011161 development Methods 0.000 description 5
230000018109 developmental process Effects 0.000 description 5
229940079593 drug Drugs 0.000 description 5
239000003480 eluent Substances 0.000 description 5
230000007717 exclusion Effects 0.000 description 5
230000008014 freezing Effects 0.000 description 5
229940050410 gluconate Drugs 0.000 description 5
239000008103 glucose Substances 0.000 description 5
235000016709 nutrition Nutrition 0.000 description 5
230000000144 pharmacologic effect Effects 0.000 description 5
229920000642 polymer Polymers 0.000 description 5
238000000746 purification Methods 0.000 description 5
239000000377 silicon dioxide Substances 0.000 description 5
238000000859 sublimation Methods 0.000 description 5
230000008022 sublimation Effects 0.000 description 5
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
230000002776 aggregation Effects 0.000 description 4
150000001323 aldoses Chemical class 0.000 description 4
238000012443 analytical study Methods 0.000 description 4
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
239000012141 concentrate Substances 0.000 description 4
238000000354 decomposition reaction Methods 0.000 description 4
239000004222 ferrous gluconate Substances 0.000 description 4
235000013924 ferrous gluconate Nutrition 0.000 description 4
229960001645 ferrous gluconate Drugs 0.000 description 4
230000014509 gene expression Effects 0.000 description 4
150000002500 ions Chemical class 0.000 description 4
VRIVJOXICYMTAG-IYEMJOQQSA-L iron(ii) gluconate Chemical compound [Fe+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O VRIVJOXICYMTAG-IYEMJOQQSA-L 0.000 description 4
229910052751 metal Inorganic materials 0.000 description 4
239000002184 metal Substances 0.000 description 4
238000000569 multi-angle light scattering Methods 0.000 description 4
239000000376 reactant Substances 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
230000009466 transformation Effects 0.000 description 4
229920002245 Dextrose equivalent Polymers 0.000 description 3
238000004220 aggregation Methods 0.000 description 3
RJGDLRCDCYRQOQ-UHFFFAOYSA-N anthrone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3CC2=C1 RJGDLRCDCYRQOQ-UHFFFAOYSA-N 0.000 description 3
239000011324 bead Substances 0.000 description 3
150000001768 cations Chemical class 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
239000013626 chemical specie Substances 0.000 description 3
238000013375 chromatographic separation Methods 0.000 description 3
239000000470 constituent Substances 0.000 description 3
230000001419 dependent effect Effects 0.000 description 3
238000009792 diffusion process Methods 0.000 description 3
238000000835 electrochemical detection Methods 0.000 description 3
238000011156 evaluation Methods 0.000 description 3
239000011261 inert gas Substances 0.000 description 3
230000004048 modification Effects 0.000 description 3
238000012986 modification Methods 0.000 description 3
229910052757 nitrogen Inorganic materials 0.000 description 3
230000003287 optical effect Effects 0.000 description 3
238000012856 packing Methods 0.000 description 3
239000002831 pharmacologic agent Substances 0.000 description 3
229920003229 poly(methyl methacrylate) Polymers 0.000 description 3
239000004926 polymethyl methacrylate Substances 0.000 description 3
230000009467 reduction Effects 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
238000012546 transfer Methods 0.000 description 3
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
WFIYPADYPQQLNN-UHFFFAOYSA-N 2-[2-(4-bromopyrazol-1-yl)ethyl]isoindole-1,3-dione Chemical compound C1=C(Br)C=NN1CCN1C(=O)C2=CC=CC=C2C1=O WFIYPADYPQQLNN-UHFFFAOYSA-N 0.000 description 2
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
241000282414 Homo sapiens Species 0.000 description 2
208000007976 Ketosis Diseases 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
230000002411 adverse Effects 0.000 description 2
208000026935 allergic disease Diseases 0.000 description 2
239000000538 analytical sample Substances 0.000 description 2
230000036783 anaphylactic response Effects 0.000 description 2
239000008346 aqueous phase Substances 0.000 description 2
229910052786 argon Inorganic materials 0.000 description 2
238000001479 atomic absorption spectroscopy Methods 0.000 description 2
230000008033 biological extinction Effects 0.000 description 2
238000004364 calculation method Methods 0.000 description 2
238000011088 calibration curve Methods 0.000 description 2
125000004432 carbon atom Chemical group C* 0.000 description 2
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
239000007795 chemical reaction product Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
239000007857 degradation product Substances 0.000 description 2
238000000502 dialysis Methods 0.000 description 2
RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
230000009977 dual effect Effects 0.000 description 2
229910001447 ferric ion Inorganic materials 0.000 description 2
229940042644 ferrlecit Drugs 0.000 description 2
239000012530 fluid Substances 0.000 description 2
239000011888 foil Substances 0.000 description 2
HYBBIBNJHNGZAN-UHFFFAOYSA-N furfural Chemical compound O=CC1=CC=CO1 HYBBIBNJHNGZAN-UHFFFAOYSA-N 0.000 description 2
230000005484 gravity Effects 0.000 description 2
239000001307 helium Substances 0.000 description 2
229910052734 helium Inorganic materials 0.000 description 2
SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
150000002505 iron Chemical class 0.000 description 2
150000002584 ketoses Chemical class 0.000 description 2
239000003446 ligand Chemical group 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
230000033116 oxidation-reduction process Effects 0.000 description 2
230000010399 physical interaction Effects 0.000 description 2
238000005086 pumping Methods 0.000 description 2
238000000197 pyrolysis Methods 0.000 description 2
238000011002 quantification Methods 0.000 description 2
238000001374 small-angle light scattering Methods 0.000 description 2
MQBDAEHWGRMADS-XNHLMZCASA-M sodium;(2r,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol;iron(3+);oxygen(2-);(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate Chemical compound [O-2].[O-2].[O-2].[Na+].[Fe+3].[Fe+3].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1.O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1.O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1.O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1.O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 MQBDAEHWGRMADS-XNHLMZCASA-M 0.000 description 2
238000000638 solvent extraction Methods 0.000 description 2
238000002798 spectrophotometry method Methods 0.000 description 2
230000035882 stress Effects 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
230000036962 time dependent Effects 0.000 description 2
238000000844 transformation Methods 0.000 description 2
230000032258 transport Effects 0.000 description 2
239000012808 vapor phase Substances 0.000 description 2
229940035081 venofer Drugs 0.000 description 2
238000012795 verification Methods 0.000 description 2
239000003643 water by type Substances 0.000 description 2
RLSFDUAUKXKPCZ-UITAMQMPSA-N (z)-3-amino-1-[3-(trifluoromethyl)-6,8-dihydro-5h-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)but-2-en-1-one Chemical compound C1CN(C(=NN=2)C(F)(F)F)C=2CN1C(=O)\C=C(/N)CC1=CC(F)=C(F)C=C1F RLSFDUAUKXKPCZ-UITAMQMPSA-N 0.000 description 1
AEQDJSLRWYMAQI-UHFFFAOYSA-N 2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 description 1
QOOMRZNLVISVGR-UHFFFAOYSA-L 2,4-dioxo-1h-pyrimidine-6-carboxylate;iron(2+) Chemical compound [Fe+2].[O-]C(=O)C1=CC(=O)NC(=O)N1.[O-]C(=O)C1=CC(=O)NC(=O)N1 QOOMRZNLVISVGR-UHFFFAOYSA-L 0.000 description 1
206010067484 Adverse reaction Diseases 0.000 description 1
206010002198 Anaphylactic reaction Diseases 0.000 description 1
208000033399 Anaphylactic responses Diseases 0.000 description 1
208000019838 Blood disease Diseases 0.000 description 1
235000002566 Capsicum Nutrition 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
238000007445 Chromatographic isolation Methods 0.000 description 1
229920000858 Cyclodextrin Polymers 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
MNQZXJOMYWMBOU-VKHMYHEASA-N D-glyceraldehyde Chemical compound OC[C@@H](O)C=O MNQZXJOMYWMBOU-VKHMYHEASA-N 0.000 description 1
102000003951 Erythropoietin Human genes 0.000 description 1
108090000394 Erythropoietin Proteins 0.000 description 1
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
239000005977 Ethylene Substances 0.000 description 1
CZNVSLGYWMSMKE-OPDGVEILSA-K Ferric gluconate Chemical compound [Fe+3].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O CZNVSLGYWMSMKE-OPDGVEILSA-K 0.000 description 1
PMVSDNDAUGGCCE-TYYBGVCCSA-L Ferrous fumarate Chemical compound [Fe+2].[O-]C(=O)\C=C\C([O-])=O PMVSDNDAUGGCCE-TYYBGVCCSA-L 0.000 description 1
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
239000005715 Fructose Substances 0.000 description 1
229930091371 Fructose Natural products 0.000 description 1
102000001554 Hemoglobins Human genes 0.000 description 1
108010054147 Hemoglobins Proteins 0.000 description 1
241000282412 Homo Species 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010022971 Iron Deficiencies Diseases 0.000 description 1
208000015710 Iron-Deficiency Anemia Diseases 0.000 description 1
102000008192 Lactoglobulins Human genes 0.000 description 1
108010060630 Lactoglobulins Proteins 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 1
229910021260 NaFe Inorganic materials 0.000 description 1
206010067482 No adverse event Diseases 0.000 description 1
239000006002 Pepper Substances 0.000 description 1
235000016761 Piper aduncum Nutrition 0.000 description 1
235000017804 Piper guineense Nutrition 0.000 description 1
244000203593 Piper nigrum Species 0.000 description 1
235000008184 Piper nigrum Nutrition 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
208000003251 Pruritus Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
238000007059 Strecker synthesis reaction Methods 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
230000009471 action Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000006838 adverse reaction Effects 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
238000005054 agglomeration Methods 0.000 description 1
150000001299 aldehydes Chemical class 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
238000012863 analytical testing Methods 0.000 description 1
208000003455 anaphylaxis Diseases 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
239000012062 aqueous buffer Substances 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
150000001540 azides Chemical class 0.000 description 1
238000010923 batch production Methods 0.000 description 1
230000008901 benefit Effects 0.000 description 1
238000010364 biochemical engineering Methods 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
238000012769 bulk production Methods 0.000 description 1
238000005515 capillary zone electrophoresis Methods 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
235000011089 carbon dioxide Nutrition 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002301 cellulose acetate Polymers 0.000 description 1
230000007012 clinical effect Effects 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
230000000536 complexating effect Effects 0.000 description 1
238000010668 complexation reaction Methods 0.000 description 1
150000004696 coordination complex Chemical group 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
229940097362 cyclodextrins Drugs 0.000 description 1
230000000593 degrading effect Effects 0.000 description 1
230000018044 dehydration Effects 0.000 description 1
238000006297 dehydration reaction Methods 0.000 description 1
239000008367 deionised water Substances 0.000 description 1
229910021641 deionized water Inorganic materials 0.000 description 1
230000000994 depressogenic effect Effects 0.000 description 1
230000001066 destructive effect Effects 0.000 description 1
239000000385 dialysis solution Substances 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
229940120503 dihydroxyacetone Drugs 0.000 description 1
230000007646 directional migration Effects 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
230000005684 electric field Effects 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
229940105423 erythropoietin Drugs 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
235000002332 ferrous fumarate Nutrition 0.000 description 1
239000011773 ferrous fumarate Substances 0.000 description 1
229960000225 ferrous fumarate Drugs 0.000 description 1
239000012467 final product Substances 0.000 description 1
238000001506 fluorescence spectroscopy Methods 0.000 description 1
230000004907 flux Effects 0.000 description 1
238000009920 food preservation Methods 0.000 description 1
230000006870 function Effects 0.000 description 1
239000005350 fused silica glass Substances 0.000 description 1
239000007789 gas Substances 0.000 description 1
239000000499 gel Substances 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
ZEKANFGSDXODPD-UHFFFAOYSA-N glyphosate-isopropylammonium Chemical compound CC(C)N.OC(=O)CNCP(O)(O)=O ZEKANFGSDXODPD-UHFFFAOYSA-N 0.000 description 1
230000012010 growth Effects 0.000 description 1
230000003394 haemopoietic effect Effects 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
208000014951 hematologic disease Diseases 0.000 description 1
208000018706 hematopoietic system disease Diseases 0.000 description 1
230000036571 hydration Effects 0.000 description 1
238000006703 hydration reaction Methods 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
230000009610 hypersensitivity Effects 0.000 description 1
238000007654 immersion Methods 0.000 description 1
230000028993 immune response Effects 0.000 description 1
239000012535 impurity Substances 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
229940090441 infed Drugs 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
150000008040 ionic compounds Chemical class 0.000 description 1
159000000014 iron salts Chemical class 0.000 description 1
230000007803 itching Effects 0.000 description 1
230000033001 locomotion Effects 0.000 description 1
230000007774 longterm Effects 0.000 description 1
238000012792 lyophilization process Methods 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
238000007726 management method Methods 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
239000002609 medium Substances 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000003607 modifier Substances 0.000 description 1
230000004001 molecular interaction Effects 0.000 description 1
231100000989 no adverse effect Toxicity 0.000 description 1
229910052755 nonmetal Inorganic materials 0.000 description 1
150000002894 organic compounds Chemical class 0.000 description 1
230000008520 organization Effects 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000005022 packaging material Substances 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000003182 parenteral nutrition solution Substances 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
239000011236 particulate material Substances 0.000 description 1
238000005192 partition Methods 0.000 description 1
238000009931 pascalization Methods 0.000 description 1
239000004417 polycarbonate Substances 0.000 description 1
229920000515 polycarbonate Polymers 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
238000004321 preservation Methods 0.000 description 1
150000003138 primary alcohols Chemical class 0.000 description 1
230000009145 protein modification Effects 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
239000013014 purified material Substances 0.000 description 1
238000000275 quality assurance Methods 0.000 description 1
239000012926 reference standard material Substances 0.000 description 1
238000005057 refrigeration Methods 0.000 description 1
239000004627 regenerated cellulose Substances 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
230000035807 sensation Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000007873 sieving Methods 0.000 description 1
239000002356 single layer Substances 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000000176 sodium gluconate Substances 0.000 description 1
235000012207 sodium gluconate Nutrition 0.000 description 1
229940005574 sodium gluconate Drugs 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
230000003595 spectral effect Effects 0.000 description 1
238000011064 split stream procedure Methods 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
150000003445 sucroses Chemical class 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
239000000725 suspension Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000003685 thermal hair damage Effects 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
230000007704 transition Effects 0.000 description 1
238000009849 vacuum degassing Methods 0.000 description 1
238000003828 vacuum filtration Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/295—Iron group metal compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
- Y10T436/143333—Saccharide [e.g., DNA, etc.]
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
- Y10T436/25125—Digestion or removing interfering materials
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
- Y10T436/25375—Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.]
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
- Y10T436/25375—Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.]
- Y10T436/255—Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.] including use of a solid sorbent, semipermeable membrane, or liquid extraction

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Inorganic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Hematology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Diabetes (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Investigating Or Analysing Biological Materials (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Investigating Or Analysing Materials By Optical Means (AREA)
Saccharide Compounds (AREA)

ZA200303284A 2000-11-02 2003-04-29 Method for producing purified hematinic iron-saccharidic complex and product produced. ZA200303284B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US24526900P	2000-11-02	2000-11-02

Publications (1)

Publication Number	Publication Date
ZA200303284B true ZA200303284B (en)	2003-11-04

Family

ID=22925992

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200303284A ZA200303284B (en)	2000-11-02	2003-04-29	Method for producing purified hematinic iron-saccharidic complex and product produced.

Country Status (12)

Country	Link
US (3)	US6537820B2 (zh)
EP (2)	EP2275075A3 (zh)
JP (2)	JP4369120B2 (zh)
CN (1)	CN1473265B (zh)
AU (1)	AU2002246556B2 (zh)
BR (1)	BR0115100A (zh)
CA (1)	CA2426799A1 (zh)
MX (1)	MXPA03003952A (zh)
PL (1)	PL361980A1 (zh)
RU (1)	RU2259197C2 (zh)
WO (1)	WO2002056826A2 (zh)
ZA (1)	ZA200303284B (zh)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6929954B2 (en) *	2000-11-02	2005-08-16	Chromaceutical Advanced Technologies, Inc.	Method for producing purified hematinic iron-saccharidic complex and product produced
PL361980A1 (en) *	2000-11-02	2004-10-18	Chromaceutical Advanced Technologies Inc.	Method for producing purified hematinic iron-saccharidic complex and product produced
US6693211B2 (en)	2002-05-15	2004-02-17	Geneva Pharmaceuticals, Inc.	Chemical process
US7169359B2 (en) *	2002-08-26	2007-01-30	Luitpold Pharmaceuticals, Inc.	Bioequivalence test for iron-containing formulations
DE10249552A1 (de)	2002-10-23	2004-05-13	Vifor (International) Ag	Wasserlösliche Eisen-Kohlenhydrat-Komplexe, deren Herstellung und diese enthaltende Arzneimittel
US20040092735A1 (en) *	2002-11-08	2004-05-13	Orchid Chemicals & Pharmaceuticals Limited	Process for the preparation of cefuroxime sodium
US20040161852A1 (en) *	2003-02-14	2004-08-19	Anderson Christopher G.	Method of assaying an Fe-Sugar complex
US7964568B2 (en) *	2003-05-30	2011-06-21	Chromaceutical Advanced Technologies, Inc.	Synthesis of high molecular weight iron-saccharidic complexes
WO2005094202A2 (en) *	2004-03-16	2005-10-13	Navinta, Llc	Iron sucrose complexes and method of manufacture thereof
US7179939B2 (en) *	2004-03-16	2007-02-20	Navinta Llc	Sodium ferric gluconate complexes and method of manufacture thereof
EP1756130A1 (de) *	2004-05-17	2007-02-28	Cilag AG	Verfahren zur herstellung von eisen (iii) gluconatkomlex
WO2006017263A1 (en)	2004-07-12	2006-02-16	Taro Pharmaceutical Industries Ltd.	Topical gel formulation comprising organophosphate insecticide and its preparation thereof
US8158139B2 (en) *	2004-07-12	2012-04-17	Taro Pharmaceuticals North America, Inc.	Topical gel formulation comprising organophosphate insecticide and preparation thereof
US20060046964A1 (en) *	2004-09-02	2006-03-02	Andre Morneau	Pharmaceutical formulations and methods
CN100528237C (zh) *	2005-04-26	2009-08-19	重庆医药工业研究院有限责任公司	多核的氢氧化铁-糖复合物的制备方法
US7560445B2 (en)	2005-07-06	2009-07-14	Taro Pharmaceuticals North America, Inc.	Process for preparing malathion for pharmaceutical use
US20080132465A1 (en) *	2006-12-05	2008-06-05	Vincent Windisch	Apparatus and method for isolating iron components from serum
JP5568551B2 (ja) *	2008-05-23	2014-08-06	ホスピラ・インコーポレイテツド	包装済み鉄スクロース製品
WO2010086832A2 (en) *	2009-01-30	2010-08-05	Ecolab Inc.	Development of an aluminum hydroxycarboxylate builder
US8202830B2 (en)	2009-01-30	2012-06-19	Ecolab Usa Inc.	Development of an aluminum hydroxydicarboxylate builder
US8536106B2 (en)	2010-04-14	2013-09-17	Ecolab Usa Inc.	Ferric hydroxycarboxylate as a builder
JP6109733B2 (ja) *	2011-03-22	2017-04-05	積水メディカル株式会社	液体クロマトグラフィー用カラム及びヘモグロビン類の分析方法
GB201304631D0 (en) *	2013-03-14	2013-05-01	Malvern Instr Ltd	Monomer detection in protein separation
CN103626807B (zh) *	2013-11-20	2017-07-07	青岛国风药业股份有限公司	一种多糖铁复合物的制备方法及其质量检测方法
US20180231511A1 (en) *	2015-08-18	2018-08-16	Shimadzu Corporation	Detector for liquid chromatography
US10258647B2 (en)	2015-09-01	2019-04-16	Particle Dynamics International, Llc	Iron-polysaccharide complexes and methods for the preparation thereof
CN107545077A (zh) *	2016-06-23	2018-01-05	中国石油化工股份有限公司	判断二元液液互溶性的方法及装置
CN110476031A (zh) *	2017-04-04	2019-11-19	日东电工株式会社	冷冻干燥体的制造方法及其制造装置
CN109959628B (zh) *	2019-04-29	2020-08-14	中南大学	一种基于极-光谱融合的锌溶液杂质离子浓度检测方法
CN119493134B (zh) *	2024-10-18	2025-08-05	中国科学院合肥物质科学研究院	基于铁原子共振荧光探测临近空间风场、温度和密度的方法及星载铁激光雷达
CN119666963A (zh) *	2024-12-31	2025-03-21	南京明捷生物医药检测有限公司	一种测定羧基麦芽糖铁注射液中二价铁含量的方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3275514A (en)	1960-04-12	1966-09-27	Paul D Saltman	Process for introduction of metals into the mammalian system
US3367834A (en)	1965-05-04	1968-02-06	Dexter Martin	Method and compositions for enhancing the utilization of iron by mammals
US3686397A (en)	1970-05-18	1972-08-22	Mueller Arthur	Parenteral iron preparations
US3821192A (en) *	1971-08-18	1974-06-28	Central Pharmacal Co	Process for preparing an iron-saccharide complex
SE359447B (zh)	1971-10-06	1973-09-03	Astra Laekemedel Ab
US4058621A (en)	1975-02-24	1977-11-15	Peter, Strong & Company, Inc.	Iron complexes and foodstuffs containing them
GB1562913A (en)	1976-06-16	1980-03-19	Fisons Ltd	Fractionating fluid mixtures of dextrans
US4180567A (en)	1977-09-02	1979-12-25	Pharmachem Corporation	Iron preparations and methods of making and administering the same
US4226983A (en)	1977-09-29	1980-10-07	United Kingdom Atomic Energy Authority	Preparation of metal complexes
US4370476A (en)	1979-07-17	1983-01-25	Usher Thomas C	Dextran polycarboxylic acids, ferric hydroxide complexes
DE3422249A1 (de)	1984-06-15	1985-12-19	Pfeifer & Langen, 5000 Köln	Wasserloesliches eisendextran und verfahren zu seiner herstellung
US5746999A (en) *	1984-11-23	1998-05-05	Schering Aktiengesellschaft	Magnetic particles for diagnostic purposes
US5254474A (en)	1991-02-25	1993-10-19	The United States Of America As Represented By The Secretary Of The Army	Method of assessing thermal processing of food using intrinsically-created compounds
US5624668A (en) *	1995-09-29	1997-04-29	Luitpold Pharmaceuticals, Inc.	Iron dextran formulations
AU1117497A (en) *	1995-11-13	1997-06-05	Albany Medical College	Analgesic compounds and uses thereof
DE19734293A1 (de) *	1997-08-08	1999-02-11	Boehringer Mannheim Gmbh	Verwendung von pharmazeutischen Kombinationspräparaten enthaltend Erythropoietin und Eisenpräparate zur Behandlung von rheumatischen Erkrankungen
US6122836A (en)	1998-05-07	2000-09-26	S.P. Industries, Inc., The Virtis Division	Freeze drying apparatus and method employing vapor flow monitoring and/or vacuum pressure control
CN1257931A (zh) *	1998-12-18	2000-06-28	吴光耀	一种可用于人体补铁的铁蛋白及其制备方法和应用
PL361980A1 (en) *	2000-11-02	2004-10-18	Chromaceutical Advanced Technologies Inc.	Method for producing purified hematinic iron-saccharidic complex and product produced
PE20021017A1 (es) *	2001-04-03	2002-11-24	Pharmacia Corp	Composicion parenteral reconstituible

2001
- 2001-10-31 PL PL01361980A patent/PL361980A1/xx not_active Application Discontinuation
- 2001-10-31 CA CA002426799A patent/CA2426799A1/en not_active Abandoned
- 2001-10-31 EP EP10011803A patent/EP2275075A3/en not_active Withdrawn
- 2001-10-31 CN CN018184006A patent/CN1473265B/zh not_active Expired - Fee Related
- 2001-10-31 WO PCT/US2001/045205 patent/WO2002056826A2/en not_active Ceased
- 2001-10-31 AU AU2002246556A patent/AU2002246556B2/en not_active Ceased
- 2001-10-31 EP EP01994129A patent/EP1330226A4/en not_active Withdrawn
- 2001-10-31 RU RU2003116134/15A patent/RU2259197C2/ru not_active IP Right Cessation
- 2001-10-31 US US09/999,394 patent/US6537820B2/en not_active Expired - Lifetime
- 2001-10-31 JP JP2002557337A patent/JP4369120B2/ja not_active Expired - Fee Related
- 2001-10-31 BR BR0115100-2A patent/BR0115100A/pt not_active Application Discontinuation
- 2001-10-31 MX MXPA03003952A patent/MXPA03003952A/es active IP Right Grant
2003
- 2003-02-21 US US10/371,783 patent/US6773924B2/en not_active Expired - Fee Related
- 2003-04-29 ZA ZA200303284A patent/ZA200303284B/en unknown
2004
- 2004-06-01 US US10/858,163 patent/US6939715B2/en not_active Expired - Fee Related
2009
- 2009-01-19 JP JP2009008909A patent/JP2009137993A/ja active Pending

Also Published As

Publication number	Publication date
US20040220141A1 (en)	2004-11-04
RU2003116134A (ru)	2005-01-10
US6773924B2 (en)	2004-08-10
EP1330226A2 (en)	2003-07-30
US20020076821A1 (en)	2002-06-20
AU2002246556B2 (en)	2006-06-01
MXPA03003952A (es)	2004-09-10
WO2002056826A3 (en)	2003-02-06
RU2259197C2 (ru)	2005-08-27
CN1473265A (zh)	2004-02-04
US6939715B2 (en)	2005-09-06
US20030153086A1 (en)	2003-08-14
EP1330226A4 (en)	2005-11-23
EP2275075A3 (en)	2011-08-10
BR0115100A (pt)	2003-09-30
US6537820B2 (en)	2003-03-25
CA2426799A1 (en)	2002-07-25
CN1473265B (zh)	2011-10-12
EP2275075A2 (en)	2011-01-19
WO2002056826A2 (en)	2002-07-25
JP4369120B2 (ja)	2009-11-18
JP2009137993A (ja)	2009-06-25
PL361980A1 (en)	2004-10-18
JP2004526132A (ja)	2004-08-26

Publication	Publication Date	Title
AU2002246556B2 (en)	2006-06-01	Method for producing purified hematinic iron-saccharidic complex and product produced
AU2002246556A1 (en)	2003-02-13	Method for producing purified hematinic iron-saccharidic complex and product produced
US8460939B2 (en)	2013-06-11	Method for producing purified hematinic iron-saccharidic complex and product produced
CA2526771C (en)	2011-04-12	Synthesis of high molecular weight iron-saccharidic complexes
Ito et al.	2012	A full validated hydrophilic interaction liquid chromatography–tandem mass spectrometric method for the quantification of oxaliplatin in human plasma ultrafiltrates
Uçaktürk	2013	The development and validation of a gas chromatography-mass spectrometry method for the determination of metformin in human plasma
BR112014021163A2 (pt)	2020-10-27	métodos analíticos aprimorados para analisar e determinar impurezas em dianidrogalactitol
CN112516090A (zh)	2021-03-19	抗体偶联药物的药物组合、冷冻干燥剂及制备方法、用途
Myers et al.	1987	High-performance liquid chromatography of ciprofloxacin and its metabolites in serum, urine and sputum
Dushkin et al.	2008	Mechanochemical preparation and pharmacological activities of water-soluble intermolecular complexes of arabinogalactan with medicinal agents
Numan et al.	2020	Utility of silver nanoparticles as coloring sensor for determination of levofloxacin in its pure form and pharmaceutical formulations using spectrophotometric technique
EP1719495A2 (en)	2006-11-08	Method for producing purified hematinic iron-saccharidic complex and product produced
Bühler	2008	Kollidon
Li	2017	Studies on the interaction of cefepime hydrochloride with bovine serum albumin by fluorescence, synchronous fluorescence, three-dimensional fluorescence and circular dichroism
Fell et al.	1979	Stability-indicating assay for azathioprine and 6-mercaptopurine by reversed-phase high-performance liquid chromatography
De Jong et al.	1992	Fully automated determination of a new anthracycline Nl-leucyldoxorubicin and six metabolites in plasma by high-performance liquid chromatography with on-line sample handling
CN112557547B (zh)	2022-08-02	用于测定氨甲苯酸冻干制剂体内行为的方法
Patil et al.	2024	BIOANALYTICAL METHOD DEVELOPMENT OF DAPAGLIFLOZIN FROM HUMAN PLASMA USING LC-MS/MS METHOD.
Ghaith et al.	2024	A High-Resolution and Rapid HPLC Method for Etamsylate Estimation from Human Plasma Escorted by The Application to a Pharmacokinetic Study
Jeon et al.	1989	Determination of L-threo-3, 4-dihydroxyphenylserine and L-α-methyldopa in rat serum by high performance liquid chromatography with fluorescence detection
Maljurić et al.	2019	The potential of Corona Charged Aerosol Detector for investigation of telmisartan-β-cyclodextrin inclusion complexes
Marcoin et al.	2009	Estimation of absorption of magnesium nicotinate and its derivatives with selected amino acids
Kato et al.	2016	A novel analytical method of cisplatin using the high-performance liquid chromatography with a naphthylethyl group bonded with silica gel (πNAP) column